Drug Profile
Research programme: small molecule ophthalmic therapies - Alcon/AstraZeneca
Latest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Alcon; AstraZeneca
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 04 Nov 2017 No recent reports of development identified for research development in Eye-disorders in Switzerland
- 22 May 2012 Early research is ongoing